News – Page 824 – Endpoints News

FDA defends its oversight of foreign drugs amid Senate, GAO criticism

5 years ago

José Baselga finds promise in new class of RNA-modifying cancer targets, locking in 3 preclinical programs with $55M

5 years ago

White House names finalists for Operation Warp Speed — with 5 expected names and one notable omission

5 years ago

Forbion leads $62.5M round for neuro startup as ex-Teva R&D chief takes control; CSL Behring inks gene therapy pact ...

5 years ago

Estimating a US price tag of $5K per course, remdesivir is set to make billions for Gilead, says key analyst

5 years ago

A low-profile biotech bests Regeneron in high-profile patent suit

5 years ago

Bullish biotech market propels Pliant to $144M IPO — as Novartis provides a $10M boost

5 years ago

Cameron Durrant hustled his way from the OTC sidelines right into the Covid-19 drug race. Death or glory lies ...

5 years ago

Is a powerhouse Merck team preparing to leap past Roche — and leave Gilead and Bristol Myers behind — in the race ...

5 years ago

Covid-19 roundup: BARDA supports Operation Warp Speed with big $628M contract to service America's vaccine production ...

5 years ago

As NLRP3 players head for first clinical face-off, Novo, Sanofi fuel trans-Atlantic contender with $55M

5 years ago

FDA delays decision on Novartis’ potential blockbuster MS drug, wiping away priority review

5 years ago

Canada’s drug price reforms delayed to 2021

5 years ago

Why Merck waited, and what they now bring to the Covid-19 fight

5 years ago

Gilead woos filgotinib clinical investigator from Stanford to lead the charge on NASH, inflammatory diseases

5 years ago

Novartis chips in $10M for IPO-bound partner Pliant; Tenax shares soar on heart drug data

5 years ago

Bristol Myers Squibb's just-launched MS drug Zeposia makes the cut in key ulcerative colitis trial

5 years ago

Once a high flyer, a staggering Aduro is auctioning off most of the pipeline as CEO Stephen Isaacs hands off the ...

5 years ago

Hillhouse recasts spotlight on China's biotech scene with $160M round for Shanghai-based antibody maker

5 years ago

Novus Therapeutics plunges deep into penny stock territory after failed ear trial

5 years ago

Stephen Hahn: FDA will make some changes amid Covid-19 permanent

5 years ago

Pfizer’s Doug Giordano has $500M — and some advice — to offer a certain breed of 'breakthrough' biotech

5 years ago

Spark touts animal data for a solution to AAV gene therapy's antibody problem

5 years ago

Gilead releases another round of murky remdesivir results

5 years ago

First page Previous page 821 822 823824825 826 827 Next page Last page